Publications & Talks
Our Research / Publications & Talks
Pre-Symptomatic and Symptomatic Biomarkers for ALS Therapy Development.
Benatar M (invited speaker). Pre-Symptomatic and Symptomatic Biomarkers for ALS Therapy Development. EverythingALS Community Event. Virtual, Sept 8, 2021.
Benatar M (panelist). Research Panel at the Florida Chapter of the ALS Association’s Annual Hope & Help Symposium. Virtual, Sept 18, 2021.
Pre-Symptomatic ALS: From natural history to early intervention and beyond.
Benatar M (invited speaker). Pre-Symptomatic ALS: From natural history to early intervention and beyond. International Meeting of Pan-Asian Consortium for Treamtent and Reseach in ALS (PACTALS). Virtual, Sept 17, 2021.
Challenging Dogma and Changing Paradigms in ALS Therapy Development.
Benatar M (invited speaker). Challenging Dogma and Changing Paradigms in ALS Therapy Development. UCSF Weill Neuroscience Institute Seminar. San Francisco, CA, Sept 2021.
Does cognition and behaviour change over time in ALS?
McHutchison C (presenter). Does cognition and behaviour change over time in ALS? Euan MacDonald Centre for MND Research Academic Afternoon. Univeristy of Edinburgh, Edinburgh, UK, June 14, 2021.
Pre-symptomatic familial ALS: The long view to disease prevention.
Benatar M (keynote speaker). Pre-symptomatic familial ALS: The long view to disease prevention. University of Pennsylvania Patient Symposium (Fighting for the Future: Education and Support for Familial FTD/ALS). Virtual, Feb 2021.
Research Update.
Benatar M (guest speaker). Research Update. University of Miami Annual ALS Patient Symposium (virtual), Jan 2021.
Design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers: The ATLAS Study
Benatar M (presenter), Wuu J, Andersen PM, Andrews J, Bucelli RC, Otto M, Ferguson TA, Chen W, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S. Design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers: The ATLAS Study. Oral presentation at the American Academy of Neurology Virtual Annual Meeting, Apr 17-22, 2021.
Frequency, hazard, and genetic risk factors of cognitive impairment in amyotrophic lateral sclerosis (ALS).
McMillan CT (presenter), Wuu J, Hennessy L, Placek K, Clinical Research in ALS (CRiALS) Study, Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, Canadian ALS Neuroimaging Consortium (CALSNIC), Quinn C, Elman L, Grossman M, Rampersaud E, Wu G, Taylor JP, Kalra S, Benatar M. Frequency, hazard, and genetic risk factors of cognitive impairment in amyotrophic lateral sclerosis (ALS). Invited presentation at the International Neuropsychological Society Annual Meeting (virtual), Feb 2-5, 2021.
Biomarkers for ALS therapy development.
Benatar M (invited speaker). Biomarkers for ALS therapy development. Seminar at the Technical Univeristy of Munich, Germany, Feb, 2021.
Symptomatic and pre-symptomatic biomarkers for ALS therapy development.
Benatar M (invited speaker). Symptomatic and pre-symptomatic biomarkers for ALS therapy development. Johns Hopkins ALS Clinical Trials Unit, Jan, 2021.
ALS Therapy Development.
Benatar M (invited speaker). ALS Therapy Development. 44th Annual Jerome K Merlis Lectureship in Neuroscience. Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, October 2020.
Conceptual framework and strategies for studying pre-symptomatic ALS.
Benatar M (presenter), Wuu J. Conceptual framework and strategies for studying pre-symptomatic ALS. 1st International Pre-Symptomatic ALS Workshop, Miami, FL, Jan 27, 2020.
Biomarkers for ALS Therapy Development.
Benatar M (invited speaker). Biomarkers for ALS Therapy Development. 5th Ottawa International Conference on Neuromuscular Disease and Biology. Ottawa, Canada, October 2019.
Biomarker Validation.
Benatar M (invited speaker). Biomarker Validation. Target ALS Annual Meeting. Boston, MA, May 2018.